Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to pseudotumor cerebri.
BACKGROUND
In pseudotumor cerebri (PTC), elevated intracranial pressure (ICP) results in papilledema and, rarely, choroidal neovascularization (CNV). Pseudotumor cerebri-induced CNV often regresses following medical or surgical ICP reduction, but additional treatments, such as photocoagulation, photodynamic therapy, peri-ocular steroid injections and/or subretinal surgery, may be necessary. Anti-angiogenic intravitreal injections have been shown to cause regression of both CNV and optic nerve edema.


METHODS
We describe a patient with PTC and CNV whose CNV regressed and vision normalized after a single intravitreal injection of bevacizumab (Avastin; Genentech, San Francisco, CA).
Jamerson
Scott C
SC
Department of Ophthalmology, West Virginia University, 1 Stadium Drive, Morgantown, WV 26506, US. sjamerson@hsc.wvu.edu
Arunagiri
Guruswami
G
Ellis
Brian D
BD
Leys
Monique J
MJ
D000086:Acetazolamide / Q000008:administration & dosage; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D004232:Diuretics / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D010211:Papilledema / Q000209:etiology; D011559:Pseudotumor Cerebri / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D011681:Pupil Disorders / Q000209:etiology; D016896:Treatment Outcome; D014792:Visual Acuity; D014794:Visual Fields
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004232:Diuretics; D000068258:Bevacizumab; D000086:Acetazolamide